Abstract
Novel noncovalent SARS-CoV-2 main protease inhibitors were designed, targeting catalytic dyad and primed binding subsites. Neutron diffraction revealed new conventional and nonconventional interactions, offering insights for future inhibitor design.
Funding Information
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK075166-01)
  • National Institutes of Health